Bio-Techne Releases Customizable 48- Digoxigenin Cartridge for Their ProteinSimple-branded Ella

Press Release Summary:

  • Allows users to perform high-quality immunoassays in under 90 minutes without manual intervention
  • Cartridge for Ella brings workflow to new areas in pharmaceutical research and development
  • It uses an anti-digoxigenin antibody on the surface of the Glass Nano Reactors to act as a universal capture

Original Press Release:

Bio-Techne Introduces 48-Digoxigenin Cartridge for The Ella Platform

Minneapolis, Jan. 29, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform. Ella allows users to perform high-quality immunoassays in under 90 minutes without manual intervention. This innovative workflow enables companies to speed up their research and empowers employees to spend their time on higher value activities. The new 48-Digoxigenin cartridge for Ella brings this unique workflow to new areas in pharmaceutical research and development by enabling researchers to build custom immunoassays on the Ella platform. The cartridge uses an anti-digoxigenin antibody on the surface of the Glass Nano Reactors (GNRs) to act as a universal capture and users can impart specificity to the GNRs by introducing their own digoxigenin-labeled reagents.

Martin Putnam, CTO, Protein Sciences Segment, Bio-Techne, commented, "We are thrilled to be able to open up the Ella platform for our customer base. This represents a new path for our customers who are studying unique biomarker signatures, pharmacokinetics, bioprocess impurities and a host of other applications that leverage custom reagents."

Dave Eansor, President of Bio-Techne's Protein Sciences Segment, commented, "Ella has brought new innovation to the standard ELISA methodology and we're extremely happy to continue that legacy of innovation by opening the platform up for development by the customer."

About Bio-Techne Corporation (NASDAQ: TECH)

Contact:

David Clair, Investor Relations

ir@bio-techne.com

646-277-1266

Source Bio-Techne Corporation

Web Site: http://www.bio-techne.com

More from Architectural & Civil Engineering Products

All Topics